JP2017061567A - セロトニン分泌促進剤 - Google Patents
セロトニン分泌促進剤 Download PDFInfo
- Publication number
- JP2017061567A JP2017061567A JP2016248224A JP2016248224A JP2017061567A JP 2017061567 A JP2017061567 A JP 2017061567A JP 2016248224 A JP2016248224 A JP 2016248224A JP 2016248224 A JP2016248224 A JP 2016248224A JP 2017061567 A JP2017061567 A JP 2017061567A
- Authority
- JP
- Japan
- Prior art keywords
- serotonin
- group
- serotonin secretion
- strain
- sbl88
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims abstract description 162
- 229940076279 serotonin Drugs 0.000 title claims abstract description 80
- 230000000580 secretagogue effect Effects 0.000 title abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 86
- 241000894006 Bacteria Species 0.000 claims abstract description 43
- 239000004310 lactic acid Substances 0.000 claims abstract description 43
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 43
- 230000001580 bacterial effect Effects 0.000 claims abstract description 29
- 240000001929 Lactobacillus brevis Species 0.000 claims abstract description 11
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 241000192001 Pediococcus Species 0.000 claims abstract description 9
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 4
- 230000028327 secretion Effects 0.000 claims description 65
- 230000017531 blood circulation Effects 0.000 claims description 36
- 230000001737 promoting effect Effects 0.000 claims description 24
- 229940039696 lactobacillus Drugs 0.000 claims description 18
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 5
- 230000002567 autonomic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims 1
- 241001468155 Lactobacillaceae Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 99
- 230000000694 effects Effects 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 230000002889 sympathetic effect Effects 0.000 description 33
- 238000005259 measurement Methods 0.000 description 26
- 210000005036 nerve Anatomy 0.000 description 26
- 239000000047 product Substances 0.000 description 23
- 230000008035 nerve activity Effects 0.000 description 22
- 230000002496 gastric effect Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 238000000540 analysis of variance Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 210000001186 vagus nerve Anatomy 0.000 description 17
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 16
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 16
- 230000005068 transpiration Effects 0.000 description 16
- 210000001367 artery Anatomy 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 210000003486 adipose tissue brown Anatomy 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000001198 duodenum Anatomy 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 8
- 229960003727 granisetron Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000000467 autonomic pathway Anatomy 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 238000000585 Mann–Whitney U test Methods 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 108091005477 5-HT3 receptors Proteins 0.000 description 2
- 102000035037 5-HT3 receptors Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000001515 vagal effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000214517 Lactobacillus casei group Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003198 cerebellar cortex Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000011392 neighbor-joining method Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- -1 troche Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
<菌体処理物の調製>
SBL88株をMRS液体培地10mL中で、1〜2日間、30℃、静置培養した。培養液を10,000rpmで10分間遠心分離し、菌体の沈殿を滅菌生理食塩水(10mL)で2回洗浄した。得られた菌体は、5mLの滅菌水に懸濁し、凍結乾燥させた。凍結乾燥した菌体を10mg/mLになるように滅菌水に懸濁した後、105℃で10分間加熱処理し、菌体溶液を得た。
COLO−320DM(JCRB0225)は(財)ヒューマンサイエンス振興財団より購入した。10%FBS含有D’MEM培地を使用し、5%CO2インキュベーター内で、COLO−320DMを3日おきに継代しながら培養した。
10%FBS含有D’MEM培地で3日間培養したCOLO−320DM培養液を、1,000rpmで5分間遠心分離して細胞を回収した。回収した細胞を、約2×105cells/mLとなるように無血清RPMI1640培地に懸濁して24穴マイクロプレートに播種した後(0.5mL/ウェル)、菌体の濃度が100質量ppmとなるように菌体溶液を添加した(1%添加)。5%CO2インキュベーター内で2時間培養した後、培養液を遠心分離して菌体及び細胞を除去した。得られた上清中のセロトニン濃度を、セロトニンEIAキット(品番900−175、コスモバイオ)を使用して測定した。菌体を添加せずに同様の操作を行った対照(菌体非添加)との比較から、SBL88株のセロトニン分泌促進作用を評価した。
SBL88株の胃迷走(副交感)神経活動、皮膚動脈交感神経活動及び褐色脂肪組織交感神経活動への作用を解析した。
SBL88株を培地(マルトース2質量%,酵母エキス1.4質量%,酢酸ナトリウム0.5質量%,硫酸マンガン0.005質量%,pH6.5〜7.0)に植菌し、30℃で1日間静置培養した。得られた培養液(約8×108cfu/mL)を、8,000rpmで10分間遠心分離して菌体を回収した。回収した菌体を蒸留水に懸濁し、8,000rpmで10分遠心分離して菌体を回収した。この操作を2度繰り返した後、蒸留水に懸濁した菌体を105℃で10分間加熱処理した後、凍結乾燥して加熱処理菌体粉末を得た。
12時間毎の明暗周期(8時〜20時まで点灯)下で、24℃の恒温動物室にて1週間以上飼育した体重約300gのWistar系雄ラット(約9週齢)を試験に使用した。試験当日は3時間絶食させた後、ウレタン麻酔し、十二指腸に菌体投与用のカニューレを挿入した。その後、胃迷走神経の遠心枝、右大腿部の皮膚動脈交感神経の遠心枝、又は背甲間の褐色脂肪組織交感神経の遠心枝を銀電極で吊り上げて、これらの神経の電気活動を測定した。測定値が落ち着いた段階(13時頃)でカニューレを使用して、加熱処理菌体粉末の懸濁液1mL(8×107cfu/mL)を十二指腸に投与し、胃迷走神経活動、皮膚動脈交感神経活動又は褐色脂肪組織交感神経活動の変化を測定した。対照として、加熱処理菌体粉末の懸濁液1mLに代えて水1mLを十二指腸に投与し、これらの神経活動の変化を測定した。測定の間、体温維持装置で体温(ラット直腸温)を35.0±0.5℃に保った。神経活動の測定データは、5分間毎の5秒あたりの発火頻度(pulse/5秒)の平均値をとり、菌体(又は水)投与前5分間の平均値(0分値)を100%とした百分率で表した。なお、測定データから平均値±標準誤差を計算すると共に、群としての統計学的有意差の検定を、反復測定分散分析(ANOVA with repeated measures)により行った。また、菌体(又は水)投与前(0分)の電気活動の測定値(絶対値)間の統計学的有意差の検定は、マン・ホイットニーのU検定(Mann−Whitney U−test)により行った。なお、各群それぞれ3匹のラットを用いた。
SBL88株の胃迷走神経亢進作用に関して、セロトニン受容体阻害剤による影響を解析した。
実施例2と同様にして、SBL88株の加熱処理菌体粉末を得た。
12時間毎の明暗周期(8時〜20時まで点灯)下で、24℃の恒温動物室にて1週間以上飼育した体重約300gのWistar系雄ラット(約9週齢)を試験に使用した。試験当日は3時間絶食させた後、ウレタン麻酔し、十二指腸に菌体投与用のカニューレを挿入した。その後、胃迷走神経の遠心枝を銀電極で吊り上げて、胃迷走神経の電気活動を測定した。測定値が落ち着いた段階(13時頃)でカニューレを使用して、加熱処理菌体粉末の懸濁液1mL(8×107cfu/mL)を十二指腸に投与した。なお、菌体投与の5分前に、ウレタン麻酔下で、頚静脈にカニューレを挿入し、0.1mLのセロトニン受容体阻害剤(後述のセロトニン受容体アンタゴニスト)溶液、又は当該溶液の溶媒を静脈内に投与した。なお、各群それぞれ1匹のラットを用いた。
Ketanserine(シグマ社製,5−HT2Aアンタゴニスト:生理食塩水に溶解させ、10μg/kgを静脈投与)
Granisetron(シグマ社製,5−HT3アンタゴニスト:生理食塩水に溶解させ、10μg/kgを静脈投与)
GR113808(シグマ社製,5−HT4アンタゴニスト:ジメチルスルホキシド(DMSO)に溶解させ、10μg/kg及び100μg/kgを静脈投与)
各種乳酸菌及びビフィズス菌の菌体調製は、実施例1の<菌体処理物の調製>と同様に行った。また、それら菌体調製液について、<COLO−320DMのセロトニン分泌促進アッセイ>を実施例1と同様に行った。その結果を図7及び8並びに表1及び2に示した。表1及び2中、セロトニン濃度が0.0のものは、測定値が検出限界(3nM/ウェル以下)以下であったことを意味する。
<菌体処理物の調製>
実施例2と同様にして、SBL88株の加熱処理菌体粉末を得た。
12時間毎の明暗周期(8時〜20時まで点灯)下で、24℃の恒温動物室にて1週間飼育した体重約300gのWistar系雄ラット(約9週齢)を試験に使用した。試験当日は3時間絶食させた後、ウレタン麻酔し、十二指腸に菌体投与用のカニューレを挿入した。その後、ラットの尾の背部表面の起始部に近い所にレーザー血流計(ALF21、アドバンス社製)のプローブ(径1cm)を外科用テープで固定し、血流の測定を開始した。測定値が安定した段階でカニューレを使用して、加熱処理菌体粉末の懸濁液1mL(8×107cfu/mL)又は水1mLを十二指腸に投与した。なお、各群それぞれ4匹のラットを用いた。
<菌体処理物の調製>
実施例2と同様にして、SBL88株の加熱処理菌体粉末を得た。
12時間毎の明暗周期(8時〜20時まで点灯)下で、24℃の恒温動物室にて1週間飼育した体重約300gの雄性HWYヘアレスラットを試験に使用した。試験期間中、ラットには、加熱処理菌体粉末の懸濁液(8×107cfu/mL)又は水を自由摂取させた。毎日13時に、背中の部位における経皮水分蒸散量(transepidermal water loss:TEWL)を、ケタミン麻酔下で、VapoMeter Delfine,Finland)を用いて測定した。なお、各群それぞれ5匹のラットを用いた。
SBL88株の皮膚動脈交感神経抑制作用に関して、セロトニン受容体阻害剤による影響を解析した。
実施例2と同様にして、SBL88株の加熱処理菌体粉末を得た。
12時間毎の明暗周期(8時〜20時まで点灯)下で、24℃の恒温動物室にて1週間以上飼育した体重約300gのWistar系雄ラット(約9週齢)を試験に使用した。試験当日は3時間絶食させた後、ウレタン麻酔し、頚静脈及び十二指腸に菌体投与用のカニーレを挿入した。その後、左大腿部の皮膚動脈交感神経の遠心枝を銀電極で吊り上げて、皮膚動脈交感神経の電気活動を測定した。測定値が落ち着いた段階(13時頃)で、0.1mLのセロトニン受容体阻害剤(上述のGranisetron)又は0.1mLの生理食塩水を静脈内に投与した。投与から5分後に加熱処理菌体粉末の懸濁液(8×107cfu/ml)を十二指腸に投与した。なお、各群それぞれ3匹のラットを用いた。
Claims (10)
- ラクトバチラス・デルブリッキィー(Lactobacillus delbrueckii)グループに属する乳酸菌以外のラクトバチラス属に属する乳酸菌、及びペディオコッカス(Pediococcus)属に属する乳酸菌からなる群より選ばれる菌株の菌体又はその処理物を有効成分として含有するセロトニン分泌促進剤。
- 前記菌株が、ラクトバチラス・ブレビス(Lactobacillus brevis)に属する菌株である、請求項1に記載のセロトニン分泌促進剤。
- 自律神経調節剤である、請求項1又は2に記載のセロトニン分泌促進剤。
- 保湿剤である、請求項1又は2に記載のセロトニン分泌促進剤。
- 血流促進剤である、請求項1又は2に記載のセロトニン分泌促進剤。
- セロトニン分泌促進作用に基づくものである、請求項3〜5のいずれか一項に記載のセロトニン分泌促進剤。
- セロトニン分泌促進用飲食品の製造における、請求項1〜6のいずれか一項に記載のセロトニン分泌促進剤の使用。
- 請求項1〜6のいずれか一項に記載のセロトニン分泌促進剤を含有するセロトニン分泌促進用医薬品。
- 請求項1〜6のいずれか一項に記載のセロトニン分泌促進剤を含有するセロトニン分泌促進用飲食品。
- 請求項1〜6のいずれか一項に記載のセロトニン分泌促進剤を含有するセロトニン分泌促進用飲食品添加物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012062127 | 2012-03-19 | ||
JP2012062127 | 2012-03-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012203208A Division JP6067292B2 (ja) | 2012-03-19 | 2012-09-14 | セロトニン分泌促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017061567A true JP2017061567A (ja) | 2017-03-30 |
JP6664315B2 JP6664315B2 (ja) | 2020-03-13 |
Family
ID=49594622
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012203208A Active JP6067292B2 (ja) | 2012-03-19 | 2012-09-14 | セロトニン分泌促進剤 |
JP2016248224A Active JP6664315B2 (ja) | 2012-03-19 | 2016-12-21 | セロトニン分泌促進剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012203208A Active JP6067292B2 (ja) | 2012-03-19 | 2012-09-14 | セロトニン分泌促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP6067292B2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6671652B2 (ja) * | 2013-06-13 | 2020-03-25 | 国立研究開発法人産業技術総合研究所 | 体温上昇剤 |
JP6353478B2 (ja) * | 2016-03-28 | 2018-07-04 | 日清食品ホールディングス株式会社 | セロトニン分泌促進能力を有するビフィズス菌 |
JP2018104387A (ja) * | 2016-12-28 | 2018-07-05 | 高梨乳業株式会社 | 皮膚動脈交感神経抑制剤 |
JP7130220B2 (ja) * | 2016-12-28 | 2022-09-05 | 高梨乳業株式会社 | 皮膚保湿剤 |
JP2020048547A (ja) * | 2018-09-03 | 2020-04-02 | イチビキ株式会社 | 乳酸菌、及びセロトニン分泌促進剤 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002171933A (ja) * | 2000-12-07 | 2002-06-18 | Ko Gijutsu Kenkyusho:Kk | キムチエキス健康食品 |
JP2003081808A (ja) * | 2001-09-13 | 2003-03-19 | Taiyo Corp | 乳酸菌発酵代謝物を含有する保湿剤及び化粧料組成物 |
WO2006030980A1 (ja) * | 2004-09-17 | 2006-03-23 | Ajinomoto Co., Inc. | 機能性消化管障害予防・改善剤及び食品 |
JP2006094747A (ja) * | 2004-09-29 | 2006-04-13 | Ajinomoto Co Inc | 抗肥満作用を有する組成物及び飲食品 |
WO2008018143A1 (fr) * | 2006-08-10 | 2008-02-14 | House Wellness Foods Corporation | Agent hydratant |
JP2008509170A (ja) * | 2004-08-12 | 2008-03-27 | ドクター カンプラド ケージー | カルビドパ/ベンセラジドを含むl−トリプトファンの新規製剤 |
WO2008120713A1 (ja) * | 2007-03-30 | 2008-10-09 | Suntory Holdings Limited | 副交感神経活動亢進作用を有する医薬組成物又は飲食物 |
JP2009137951A (ja) * | 2007-11-15 | 2009-06-25 | Poonsook Lohajoti | 皮膚保湿剤、血行促進剤、およびそれらを含有する皮膚外用剤 |
JP2009242255A (ja) * | 2008-03-28 | 2009-10-22 | National Agriculture & Food Research Organization | プラスミノーゲン活性化剤 |
JP2011523407A (ja) * | 2008-05-16 | 2011-08-11 | ネステク ソシエテ アノニム | ラクトバチルス・パラカゼイと体重管理 |
JP2012017282A (ja) * | 2010-07-07 | 2012-01-26 | Calpis Co Ltd | 迷走神経活性化剤 |
JP5967527B2 (ja) * | 2012-06-22 | 2016-08-10 | 国立研究開発法人産業技術総合研究所 | 食欲増進かつ体重増加抑制剤 |
-
2012
- 2012-09-14 JP JP2012203208A patent/JP6067292B2/ja active Active
-
2016
- 2016-12-21 JP JP2016248224A patent/JP6664315B2/ja active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002171933A (ja) * | 2000-12-07 | 2002-06-18 | Ko Gijutsu Kenkyusho:Kk | キムチエキス健康食品 |
JP2003081808A (ja) * | 2001-09-13 | 2003-03-19 | Taiyo Corp | 乳酸菌発酵代謝物を含有する保湿剤及び化粧料組成物 |
JP2008509170A (ja) * | 2004-08-12 | 2008-03-27 | ドクター カンプラド ケージー | カルビドパ/ベンセラジドを含むl−トリプトファンの新規製剤 |
WO2006030980A1 (ja) * | 2004-09-17 | 2006-03-23 | Ajinomoto Co., Inc. | 機能性消化管障害予防・改善剤及び食品 |
JP2006094747A (ja) * | 2004-09-29 | 2006-04-13 | Ajinomoto Co Inc | 抗肥満作用を有する組成物及び飲食品 |
WO2008018143A1 (fr) * | 2006-08-10 | 2008-02-14 | House Wellness Foods Corporation | Agent hydratant |
WO2008120713A1 (ja) * | 2007-03-30 | 2008-10-09 | Suntory Holdings Limited | 副交感神経活動亢進作用を有する医薬組成物又は飲食物 |
JP2009137951A (ja) * | 2007-11-15 | 2009-06-25 | Poonsook Lohajoti | 皮膚保湿剤、血行促進剤、およびそれらを含有する皮膚外用剤 |
JP2009242255A (ja) * | 2008-03-28 | 2009-10-22 | National Agriculture & Food Research Organization | プラスミノーゲン活性化剤 |
JP2011523407A (ja) * | 2008-05-16 | 2011-08-11 | ネステク ソシエテ アノニム | ラクトバチルス・パラカゼイと体重管理 |
JP2012017282A (ja) * | 2010-07-07 | 2012-01-26 | Calpis Co Ltd | 迷走神経活性化剤 |
JP5967527B2 (ja) * | 2012-06-22 | 2016-08-10 | 国立研究開発法人産業技術総合研究所 | 食欲増進かつ体重増加抑制剤 |
Non-Patent Citations (4)
Title |
---|
B. J. NUTRITION, vol. 105, JPN6016024570, 2011, pages 755 - 64, ISSN: 0003614045 * |
BIOL. PHARM. BULL., vol. 31(5), JPN6016024569, 2008, pages 884 - 9, ISSN: 0003614046 * |
BR. J. PHARMAC., vol. 82, JPN6016039198, 1984, pages 817 - 26, ISSN: 0003614044 * |
食品と容器, vol. 47(9), JPN6016039197, 2006, pages 544 - 50, ISSN: 0003614043 * |
Also Published As
Publication number | Publication date |
---|---|
JP6067292B2 (ja) | 2017-01-25 |
JP6664315B2 (ja) | 2020-03-13 |
JP2013224287A (ja) | 2013-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6664315B2 (ja) | セロトニン分泌促進剤 | |
US8492442B2 (en) | Medicinal composition, food or drink having effect of enhancing parasympathetic nervous activity | |
KR102206628B1 (ko) | 비만의 예방 또는 치료 효과를 가지는 신규 락토바실러스 람노서스 균주 및 이의 용도 | |
JP6986067B2 (ja) | 脱毛症防止、発毛促進または性機能改善能を有するリューコノストック・ホルザプフェリイ菌株及びこれを含む組成物 | |
JP7323510B2 (ja) | 睡眠促進用組成物並びに該睡眠促進用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP5203393B2 (ja) | アルコール性肝障害抑制剤 | |
JP5943342B2 (ja) | 概日リズム改善剤 | |
JP5945092B2 (ja) | 中性脂肪低減剤 | |
CN113543659A (zh) | 包含意外片球菌的用于预防、改善或治疗神经退行性疾病的组合物 | |
JP5254682B2 (ja) | 経口摂取用皮膚性状改善剤 | |
JPWO2015133122A1 (ja) | 鎮静用の自律神経調整剤及び日周リズム改善剤 | |
KR20140142170A (ko) | 락토바실러스 브레비스 g-101 및 이의 용도 | |
JP2010083881A (ja) | 腸管保護剤 | |
AU2017287987A1 (en) | Cartilage regeneration facilitating composition | |
ES2763874B2 (es) | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades | |
JP2014005225A (ja) | 食欲増進かつ体重増加抑制剤 | |
JP6654639B2 (ja) | 血中トリプトファン濃度上昇抑制剤 | |
JP2021529183A (ja) | 酵母抽出物を含む糖尿改善または抗酸化用の組成物と酵母抽出物の製造方法 | |
JP7430312B2 (ja) | 腸内短鎖脂肪酸産生促進用組成物及びこれを含む飲食品 | |
EP3978075A1 (en) | Walking ability improver | |
US20240108665A1 (en) | Composition for preventing, alleviating or treating sleep disorders, containing, as active ingredient, gut microbiota or extracellular vesicles derived therefrom | |
KR20230160117A (ko) | 프레보텔라 히스티콜라 kcom 4227 | |
KR20230160115A (ko) | 프레보텔라 히스티콜라 kcom 4081 | |
KR20230160116A (ko) | 프레보텔라 히스티콜라 kcom 3796 | |
KR20220112192A (ko) | 장내 미생물 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161222 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171006 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180404 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180418 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190724 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6664315 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |